September 15, 2015 | Minaris Regenerative Medicine News

Spreading the Word on the Future of Commercial Cell Therapy Manufacturing– PCT Heads to IBC

At the end of this month, two of my colleagues and I have the opportunity to speak at the IBC Life Sciences Cell Therapy Bioprocessing and Commercialization Conference in Alexandria, Virginia.

New_Preti

On September 30 during the conference, I will be giving a presentation entitled, “Partnering with a CMO along the Road to Commercial Cell Therapy Manufacturing.”

From me, you’ll be hearing about the three main hurdles to a commercial future for cell therapy: 

1) The current state of manufacturing potentially leading to unsustainable products
2) Idle capacity in cleanrooms and manufacturing facilities driving cost of goods to unreasonable levels
3) Scalability from clinical- to commercial-level manufacturing

For each of these challenges, PCT offers strategic, practical recommendations to help cell therapy developers work towards successful commercialization. Topics I’ll cover include:

           - Deliverability
           -
Comparability risk
           -
The need for strategic commercial manufacturing planning
           -
Challenges of a single-product manufacturing facility
           -
Commercial quality and cGMP infrastructure systems implementation
           -
The consortium model for commercial manufacturing

I look forward to discussing each of these points in more detail during the IBC conference, and I hope to see many of you at the event.

 In addition to my presentation, two of my colleagues will also be speaking at IBC:

  • On October 1, I will be moderating a panel on which my colleague, Ann Daus, PhD, Vice President, Quality Assurance and Quality Control, will be speaking on the topic of “Alignment with Commercialization: Addressing the Fundamental Challenges of Bringing Cell Therapies to Market

  • Also on October 1, my colleague Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, will be delivering a presentation entitled,What Can Automation Do for You and When – Strategic Considerations, Examples and Lessons Learned”

To request a download of the complementary PCT presentation, “Partnering with a CMO Along the Road to Commercial Cell Therapy Manufacturing,” click on the button below. Once you request the download, your presentation will be delivered to you after the IBC conference.

 New Call-to-action

 

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date on the latest cell therapy industry insights

Related Articles

January 9, 2018

5 Considerations in the Preparation for Commercializing Cell Therapy

Cell therapy is still a relatively new form of treatment. As such, not that many cell therapies have successfully reached commercialization. Meeting FDA requirements at each phase of the ...

Read More
March 23, 2017

Moving Toward Controlled, Non-Classified Space For Cell Therapies

Despite the advances the cell therapy industry has made in recent years, commercially viable manufacturing continues to be an elusive challenge. In order for the cell therapy industry to ...

Read More
June 8, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 2

This is the second in a three-part series (Part 1 can be found here). As you enter this mid-phase of development, we reflect on these words from Albert Einstein: “In the middle of ...

Read More